Abbott Diagnostics generates approximately $12 billion in IVD revenues in 2025, with leading positions in immunoassay, clinical chemistry, molecular diagnostics, and point-of-care testing across its Core Laboratory and Rapid Diagnostics divisions. The Alinity family — Alinity c for clinical chemistry, Alinity i for immunoassay, and Alinity m for molecular — represents Abbott's fully integrated laboratory automation strategy. The ID NOW platform received CE marking for its 2.0 enhanced version in January 2025, optimized for COVID-19 and flu dual detection, with over 50,000 instruments deployed globally. Abbott's BinaxNOW rapid antigen portfolio demonstrated the commercial power of decentralized diagnostics at population scale. Abbott reports 9.5-10% organic sales growth with $1.65-$1.68 billion in Q1 2025 revenue guidance.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Alinity Consolidation, ID NOW Expansion, and POC Leadership Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Alinity, ID NOW, BinaxNOW, and Abbott Diagnostics IP
• Latest Products and Services — Platform Launches, Menu Expansions, and Innovation Pipeline
• M&A — Acquisitions, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Reagent Rental Strategy, GPO Positioning, and Channel Approach
• Organization and Management — Leadership, Structure, and Workforce
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant developments 2024-2025
- Strategic recommendations
2. Strategic Directions
- Portfolio strategy and capital allocation priorities
- Technology investment focus areas
- Geographic expansion and market development
- Growth priorities through 2030
3. Financial Performance
- Revenue and revenue growth 2023-2025
- Revenue by segment 2023-2025
- Revenue by geography 2023-2025
- Operating income, margins, and EBITDA 2023-2025
- R&D investment 2023-2025
4. SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
5. Technological Know-How
- Core technology capabilities and IP portfolio
- AI and digital diagnostics investments
- Key platform systems and technology milestones
6. Latest Products and Services
- Recent product and platform launches 2023-2025
- Key analyzer and reagent portfolio
- Innovation pipeline and development programs
7. M&A
- Acquisitions, divestitures, and partnerships 2023-2025
8. Marketing Tactics
- Segment and channel positioning
- Reagent rental and placement strategy
- Key account and GPO strategy
9. Organization and Management
- Leadership and executive team
- Organizational structure and key changes
- Workforce size and developments
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Abbott Diagnostics — Key Financial Metrics Summary 2023-2025
Table 2. Abbott Diagnostics — Revenue by Segment 2023-2025
Table 3. Abbott Diagnostics — Revenue by Geography 2023-2025
Table 4. Abbott Diagnostics — R&D Investment 2023-2025
Table 5. Abbott Diagnostics — SWOT Analysis
Table 6. Abbott Diagnostics — Core Technology Capabilities and Key Platforms
Table 7. Abbott Diagnostics — Key Analyzers and Reagent Portfolio
Table 8. Abbott Diagnostics — M&A Activity Summary 2023-2025
Table 9. Abbott Diagnostics — Key Management and Leadership
Table 10. Abbott Diagnostics — Strategic Priorities 2025-2030
